chenzo 11, LOL. Methinks the Chinese and Russians, if not PPHM brass, owe us some data points on PPHM products licensed and tested in their countries. Don't they publish any negatives? non-starters?
What happened to Cotara for lung cancer in China, and 2C3, and TTF, and, and....These are all very good intellectual properties awaiting patent expiration, etc. So if the incoming money tide is from off-shore it is probably a sleeper. If the money is mostly domestic, then it is probably the exosome cancer detection strategy, a clinical winner IMHO. (Disclaimer: I have thought previous PPHM therapies to be winners too). Since we are now talking diagnosis, we are talking much less trial time and much wider application. From a medical practitioner's point of view, mind-boggling, really.
Market Data 
Markets 
AI
